Investigators Identify Predictors or Poor Outcomes for Patients with Stable Coronary Artery Disease

November 16, 2021
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

Treatment with statins, nitrates, dihydropyridines, verapamil, and proton-pump inhibitors were predictors of death or ischemic events for patients in the HGFR group.

Investigators have identified a number of predictors for ischemic events or death for patients with stable coronary artery disease (SCAD) in data presented at the annual American Heart Association (AHA) 2021 Meeting.

A team, led by Alvaro Acena, MAdrid, assessed the influence of estimated glomerular filtration rate (eGFR) on predicting Parathormone (PTH) and other Mineral Metabolism (MM) markers in patients with SCAD.

Forecasting Problems

Parathormone, part of the Mineral Metabolism system, has recently shown value in forecasting stable coronary artery disease and average renal function.

However, it is uncertain what the influence of renal function on forecasting PTH on patients with SCAD might be.

In the study, the investigators analyzed the prognostic value of different markers, including PTH, klotho, phosphate, calcidiol (25-hydroxyvitamin D3), and fibroblast growth factor-23 [FGF-23].

The study included 964 patients with SCAD and an eGFR <60 ml/min/1.73 m2 (LGFR), which were compared to patients with eGFR≥60 ml/min/1.73 m2 (HGFR) at 5 hospitals in Spain.


The investigators sought main outcomes of the combination of death with ischemic events based on any acute coronary syndrome, ischemic stroke, or transient ischemic attack. They calculated eGFR using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI).

Overall, 790 patients had HGFR and 174 participants had LGFR.

The predictors of ischemic events or death were plasma levels of calcidol [HR, 0.023; 95% CI, 0.94-0.99; P = 0.023], FGF23 [HR, 1.00; 95% CI, 1.00-1.003; P = 0.036], non-HDL cholesterol [HR, 1.01; 95% CI, 1.00-1.01; P = 0.026], and high sensitivity troponin [HR, 5.12; 95% CI, 1.67-15.59; P = 0.004 in the HGFR group]. Age was also a predictor (HR, 1.03; 95% CI, 1.01-1.05; P = 0.01].

Other predictors also included treatment with statins [HR, 0.36; 95% CI, 0.19-0.68; P = 0.002], nitrates [HR, 1.13; 95% CI, 1.07-2.79; P = 0.027], dihydropyridines [HR, 1.71; 95% CI, 1.05-2.77; P = 0.032], verapamil [HR, 5.71; 95% CI, 1.35-24.1; P = 0.018], and proton-pump inhibitors [HR, 2.23; 95% CI, 1.36-3.68; P = 0.002].

There were some similarities in the LGFR cohort. Predictors of death or ischemic events in this group were PTH plasma levels, [HR, 1.01; 95% CI, 1.00-1.01; P = 0.005], the eGFR [HR, 0.96; 95% CI, 0.94-0.99; P = 0.004], age [HR, 1.06; 95% CI, 1.02-1.10; P = 0.003], Caucasian race [HR, 0.04; 95% CI, 0.004-0.380; P = 0.005], and treatment with insulin [HR, 2.6; 95% CI, 1.20-5.63; P = 0.015].

“In [patients] with SCAD, PTH is an independent predictor of poor outcomes only in those with eGFR<60 ml/min/1.73 m2 , while in [patients] with eGFR≥60 ml/min/1.73 m2 calcidiol and FGF-23 become the only components of MM that may predict prognosis,” the authors wrote. “Then, renal function influences the predictive power of MM markers in [patients] with SCAD.”

The study, “Mineral Metabolism Predictors of Poor Outcomes in Stable Coronary Artery Disease With and Without Impaired Renal Function,” was published online by AHA.